Soleno shares fell double digits amid questions concerning the development trajectory of its Prader-Willi drug. Elsewhere, a most cancers medication on the heart of a $1.9 billion buyout fell quick in a key trial.
Elevate your perspective with NextTech Information, the place innovation meets perception.
Uncover the most recent breakthroughs, get unique updates, and join with a world community of future-focused thinkers.
Unlock tomorrow’s developments right now: learn extra, subscribe to our publication, and turn out to be a part of the NextTech neighborhood at NextTech-news.com
